High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359231220510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 06.01.2024. Verfasst von Nithya Krishnamurthy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, RK is funded.
Abstract (Originalsprache)
Background
CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.
Objective
To assess the prognostic implications and immunologic correlates of high CTLA-4 in tumors of patients on immunotherapy and those on non-immunotherapy treatments. Design/methods: We evaluated RNA expression levels in a clinical-grade laboratory and clinical correlates of CTLA-4 and other immune checkpoints in 514 tumors, including 489 patients with advanced/metastatic cancers and full outcome annotation. A reference population (735 tumors; 35 histologies) was used to normalize and rank transcript abundance (0–100 percentile) to internal housekeeping gene profiles.
Results
The most common tumor types were colorectal (140/514, 27%), pancreatic (55/514, 11%), breast (49/514, 10%), and ovarian cancers (43/514, 8%). Overall, 87 of 514 tumors (16.9%) had high CTLA-4 transcript expression (⩾75th percentile rank). Cancers with the largest proportion of high CTLA-4 transcripts were cervical cancer (80% of patients), small intestine cancer (33.3%), and melanoma (33.3%). High CTLA-4 RNA independently/significantly correlated with high PD-1, PD- L2, and LAG3 RNA levels (and with high PD-L1 in univariate analysis). High CTLA-4 RNA expression was not correlated with survival from the time of metastatic disease [ N = 272 patients who never received immune checkpoint inhibitors (ICIs)]. However, in 217 patients treated with ICIs (mostly anti-PD-1/anti-PD- L1), progression-free survival (PFS) and overall survival (OS) were significantly longer among patients with high versus non-high CTLA-4 expression [hazard ratio, 95% confidence interval: 0.6 (0.4–0.9) p = 0.008; and 0.5 (0.3–0.8) p = 0.002, respectively]; results were unchanged when 18 patients who received anti-CTLA-4 were omitted. Patients whose tumors had high CTLA-4 and high PD-L1 did best; those with high PD-L1 but non-high CTLA-4 and/or other expression patterns had poorer outcomes for PFS ( p = 0.004) and OS ( p = 0.009) after immunotherapy.
Conclusion
High CTLA-4, especially when combined with high PD-L1 transcript expression, was a significant positive predictive biomarker for better outcomes (PFS and OS) in patients on immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574, USA.
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.
- Dartmouth Cancer Center, Hematology and Medical Oncology, Lebanon, NH, USA.
- OmniSeq Inc. (Labcorp), Buffalo, NY, USA.
- MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA.
- WIN Consortium, Paris, France.
ORCID-Profile: Nithya Krishnamurthy
Förderung
- NCI NIH HHS
- RK is funded
Zitieren
APA
Krishnamurthy, N., Nishizaki, D., Lippman, S. M., Miyashita, H., Nesline, M. K., Pabla, S., Conroy, J. M., DePietro, P., Kato, S., & Kurzrock, R. (2024). High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359231220510
Vancouver
Krishnamurthy N, Nishizaki D, Lippman SM, Miyashita H, Nesline MK, Pabla S, et al. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231220510
BibTeX
@article{Krishnamurthy2024,
author = {Krishnamurthy, Nithya and Nishizaki, Daisuke and Lippman, Scott M and Miyashita, Hirotaka and Nesline, Mary K and Pabla, Sarabjot and Conroy, Jeffrey M and DePietro, Paul and Kato, Shumei and Kurzrock, Razelle},
title = {High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359231220510}
}
EUVIMED